Basic Novonorm Information

• INN (International Nonproprietary Name): Repaglinide
• Brand Names Available In United Kingdom: NovoNorm (used across European markets); other global brands include Prandin, Gluconorm and Surepost
• ATC Code: A10BX02
• Forms & Dosages: Tablets 0.5 mg, 1 mg and 2 mg
• Manufacturers In United Kingdom: Not specified
• Registration Status In United Kingdom: Not specified
• OTC / Rx Classification: Prescription only (Rx) in all known territories

Key Findings From Recent Trials

Worried about post‑meal spikes despite diet and exercise?

Recent clinical research from 2022 to 2025 focused on repaglinide’s role in reducing post‑prandial glucose excursions and as an add‑on to metformin or basal insulin.

Trials generally used typical titration schemes beginning 0.5–1 mg before meals and allow up‑titration to 4 mg per meal and 16 mg per day where needed.

Major 2022–2025 Studies

Which trials matter for practice in the United Kingdom?

Randomised controlled trials and pooled analyses examined repaglinide for targeted prandial control and compared it with placebo and other mealtime secretagogues.

Many trials enrolled adults with type 2 diabetes inadequately controlled on diet or with metformin and used dosing per meal consistent with the repaglinide SPC.

Main Outcomes

What did the studies show about glucose control?

Across studies, repaglinide produced consistent reductions in post‑meal glucose excursions versus placebo when dosed before meals.

When compared with other rapid‑acting secretagogues, repaglinide was generally non‑inferior for HbA1c reduction when used per meal.

Its short action profile translated into improved post‑prandial metrics rather than major fasting glucose changes.

Safety Observations

What safety signals should clinicians watch for?

Hypoglycaemia remains the principal safety concern, especially when repaglinide is combined with other insulin secretagogues or insulin itself.

Renal and hepatic impairment increased the risk of prolonged or severe hypoglycaemia and warranted dose caution or contraindication in severe liver disease.

Concomitant gemfibrozil use repeatedly produced severe hypoglycaemia in reports and is contraindicated.

Cardiovascular outcome data are limited compared with newer classes such as SGLT2 inhibitors and DPP‑4 inhibitors, so repaglinide is not positioned for CV risk modification.

Clinical Mechanism Of Action

Curious how repaglinide works at mealtimes?

Repaglinide is a rapid‑acting oral medicine taken with meals to prompt the pancreas to release insulin quickly and blunt post‑meal glucose rises.

Layman’s Explanation

How would a patient describe it?

Taken just before a meal, repaglinide encourages a quick burst of insulin so blood sugar does not spike after eating.

Its short duration makes it suitable for people with variable mealtimes who need targeted prandial control rather than continuous insulin exposure.

Scientific Breakdown

What is the pharmacological class and mechanism?

Repaglinide is a meglitinide (glinide) and works by transiently closing KATP channels on pancreatic β‑cells, which triggers rapid insulin secretion.

The ATC classification is A10BX02, grouping it with other oral blood glucose‑lowering agents in the meglitinide class.

Onset is rapid when dosed 0–30 minutes before a meal and the drug’s short action reduces prolonged insulin exposure compared with many sulfonylureas.

Pharmacokinetics & Dynamics

What are the practical PK/PD points for prescribing?

Repaglinide tablets are available in 0.5, 1 and 2 mg strengths for flexible dosing at each main meal.

Typical starting doses are 0.5–1 mg before a meal with weekly titration to effect up to 4 mg single dose and 16 mg daily maximum.

These features define its clinical niche as a targeted prandial glucose regulator suitable where mealtime control is the priority.

Scope Of Approved And Off‑Label Use

Who is repaglinide approved for and who might use it off‑label?

Repaglinide is authorised for adults with type 2 diabetes as an adjunct to diet and exercise.

United Kingdom Approvals

What does the licence cover?

The authorised indication is type 2 diabetes mellitus in adults as an adjunct to diet and exercise.

Typical SPC dosing begins at 0.5 mg per main meal for lower HbA1c and 1 mg when HbA1c is higher, with weekly titration to a maximum of 4 mg per meal and 16 mg daily.

Notable Off‑Label Trends

When do prescribers turn to repaglinide outside the headline indication?

Clinicians sometimes choose repaglinide for adults with irregular meal schedules such as shift workers who need short‑acting mealtime coverage.

It is not established for use in children and is contraindicated in severe hepatic impairment.

NICE guidance still prioritises metformin as first line, making repaglinide a second‑line or niche option in many UK pathways.

Dosage Strategy

How should dosing be started and adjusted in everyday practice?

General Dosing

What are the standard strengths and initiation rules?

Available tablet strengths are 0.5 mg, 1 mg and 2 mg.

Start adults at 0.5 mg with each main meal if HbA1c is less than 8% and at 1 mg if HbA1c is 8% or more.

Increase weekly guided by self‑monitoring up to 4 mg per meal and a total daily limit of 16 mg.

Administer 0–30 minutes before meals and skip the dose if the meal is missed.

Condition‑Specific Dosing

How do comorbidities change dosing decisions?

In renal impairment start at the lowest dose of 0.5 mg and titrate cautiously while monitoring closely for hypoglycaemia.

Repaglinide is contraindicated in severe hepatic impairment and should be used with caution in mild to moderate liver dysfunction.

Elderly patients often require lower initiation doses and closer monitoring for hypoglycaemia.

Titration & Monitoring

What does safe dose escalation look like?

Perform weekly titration based on SMBG readings and periodic HbA1c measurements to track overall control.

When combining repaglinide with sulfonylureas or insulin, adjust co‑therapies to reduce hypoglycaemia risk.

Safety Protocols

What should patients and pharmacists be most concerned about?

Contraindications

Who should not receive repaglinide?

Absolute contraindications include type 1 diabetes, diabetic ketoacidosis and known hypersensitivity to repaglinide or any excipients.

Concomitant gemfibrozil is a strict contraindication due to reported severe hypoglycaemia.

Severe hepatic impairment is also an absolute contraindication.

Adverse Effects

What side effects are commonly reported?

The most common adverse event is hypoglycaemia, which may be mild to severe depending on co‑medication and patient factors.

Other reported effects include headache, upper respiratory tract infections and back pain.

Gastrointestinal upset and arthralgia have been observed less frequently.

Monitoring Recommendations

What baseline and ongoing checks are appropriate?

Obtain baseline HbA1c plus renal and liver function tests before initiation.

Encourage regular SMBG around meals while titrating and after dose changes.

Provide clear patient education on recognising and treating hypoglycaemia, including when to seek emergency care.

Interaction Mapping

Which drugs and foods commonly cause trouble with repaglinide?

Food Interactions

Are there dietary risks to be aware of?

Alcohol potentiates hypoglycaemic episodes and should be avoided or used cautiously while taking repaglinide.

Because dosing is linked to meals, skipping food should lead to skipping that dose to prevent hypoglycaemia.

Drug Combinations To Avoid

Which medicines are clear red flags?

Gemfibrozil is contraindicated because co‑administration has led to severe hypoglycaemia in multiple reports.

Concurrent insulin or sulfonylureas increases hypoglycaemia risk and usually requires dose reductions of the other agent.

Strong CYP inhibitors or inducers can change repaglinide exposure; consult the SPC when prescribing interacting drugs.

Metabolic Pathways & Practical Tips

How do metabolic pathways influence safe use?

Repaglinide’s rapid onset and short duration mean transient interactions at mealtimes can still be clinically important.

Coordinate medication timing, review lipid‑lowering regimens and regularly review polypharmacy in older adults.

Patient Experience Analysis

What do people who use repaglinide actually say?

Survey Data

How do patients rate mealtime control?

UK and EU diabetes cohort surveys highlight strengths for those worried about post‑meal spikes and for people with irregular eating patterns.

Reported benefits include perceived improvement in mealtime glucose control and flexibility when meals are variable.

Trade‑offs noted are a greater need for frequent glucose monitoring and occasional hypoglycaemia.

Forum Trends

What do online patient groups mention most?

Forums commonly praise NovoNorm for prandial control and flexibility, with users often comparing it favourably to longer‑acting secretagogues.

Complaints frequently relate to hypoglycaemia, cost and pharmacy availability compared with metformin.

Carers and older patients emphasise the need for clear guidance on dosing timing and hypoglycaemia management.

Distribution And Pricing Landscape

How easy is it to get repaglinide in the UK and what does it cost?

Manufacturers & Brands

Who makes repaglinide tablets?

Novo Nordisk is the primary innovator and global supplier of brand product NovoNorm.

Authorized generics and other local producers exist, including Gemini Laboratories and manufacturers in regions such as India and Egypt.

Packaging is usually blister strips or HDPE bottles with a patient information leaflet in the local language.

Availability In The United Kingdom

Can patients obtain novonorm locally?

Repaglinide (often marketed as NovoNorm) is prescription only in known territories and is available through NHS prescribing where clinically indicated.

Use is less common than metformin and newer oral agents, and local formularies influence which brand or generic is preferred.

In our online pharmacy, novonorm is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Which medicines could be chosen instead of repaglinide?

Comparison Table Summarised

Which drug classes compete for the same role?

Alternatives include sulfonylureas (glipizide, gliclazide, glimepiride), another meglitinide (nateglinide), metformin, DPP‑4 inhibitors and SGLT2 inhibitors.

Pros And Cons

How do these options stack up in practice?

Repaglinide offers rapid prandial control and flexibility for irregular meals but carries hypoglycaemia risk and lacks strong cardiovascular outcome data.

Sulfonylureas are inexpensive and effective but often have longer duration and greater fasting hypoglycaemia risk.

DPP‑4 inhibitors and SGLT2 inhibitors provide weight neutrality or cardiorenal benefits but do not specifically target post‑prandial spikes in the same way.

Regulatory Status

Where is repaglinide approved and who regulates it?

Global Approvals

Which agencies have authorised repaglinide?

Repaglinide has long‑standing approvals including FDA (Prandin) in the USA since 1997, EMA authorisation in the EU (NovoNorm), Health Canada (Gluconorm) and approvals in Japan and other markets.

It is prescription only across known jurisdictions.

UK And EU Specifics

How should UK prescribers check current status?

NovoNorm is authorised in various European countries and the MHRA is the UK regulator post‑Brexit.

Prescribers should consult the SPC and local formularies for up‑to‑date licensing, supply and prescribing notes.

Consolidated FAQ

Which questions do patients and clinicians ask most?

Common Patient Questions

What if I miss a dose?

If a meal is skipped, skip that dose; do not double up at the next meal.

Can repaglinide cause weight gain?

Some patients may experience modest weight gain similar to other insulin secretagogues; lifestyle advice is important.

Can it be used with metformin?

Yes, combination with metformin is common when both fasting and post‑prandial control are required, but monitor for hypoglycaemia.

Clinician Quick Answers

Is it safe in elderly patients?

Use caution, start low and monitor renal and hepatic function closely.

How should it be stored?

Store at 25°C with permitted excursions between 15–30°C and keep in original packaging until use.

Is gemfibrozil safe?

No; co‑administration is contraindicated due to risk of severe hypoglycaemia.

Visual Guide

Which images help explain repaglinide to patients and clinicians?

Suggested Figures & Charts

Helpful visuals include a PK/PD curve comparing repaglinide’s rapid onset and short duration with sulfonylureas.

A dosing flowchart illustrating start at 0.5–1 mg per meal, weekly titration and maximum doses simplifies counselling.

An interaction map highlighting gemfibrozil and insulin/sulfonylurea combinations clarifies safety points.

A patient‑centred infographic on recognising and treating hypoglycaemia is essential for home use.

Packaging & Labelling Notes

What should packaging images show?

Show examples of NovoNorm blister packs and tablet strengths 0.5, 1 and 2 mg and include PI highlights for UK labelling compliance.

Alt text should describe strength, dosing timing and storage instructions such as store at 25°C with permitted excursions between 15–30°C.

Storage And Transport

How should pharmacies and patients store repaglinide?

Temperature & Packaging

Recommended storage is 25°C with permitted excursions of 15–30°C.

Protect tablets from moisture and heat and keep in original blister strip or bottle with the patient information leaflet.

Pharmacy Handling

What should dispensers include on labels?

Ensure labelling indicates prescription status and the dosing timing (take 0–30 minutes before meals).

Avoid prolonged exposure to humidity or temperature extremes during distribution and remove expired stock according to local waste protocols.

Advise patients to keep tablets away from bathrooms and sunlight and to follow expiry and disposal guidance.

Guidelines For Proper Use

Who is the right candidate and how should therapy be stopped when appropriate?

Patient Selection & Initiation

Choose repaglinide for adults with type 2 diabetes who need targeted prandial control or who cannot tolerate metformin.

Avoid use in type 1 diabetes, diabetic ketoacidosis and severe hepatic impairment.

Start at 0.5–1 mg with main meals and titrate weekly according to SMBG and HbA1c.

Monitoring & Deprescribing

Monitor renal and hepatic function and educate patients on hypoglycaemia recognition and treatment.

Deprescribe by stopping per‑meal doses as glucose stabilises and transition to alternative regimens following NICE and MHRA guidance.

When switching to agents with overlapping hypoglycaemia risk, reduce doses appropriately and monitor closely for several days to weeks.

Delivery Across United Kingdom

Final Notes For Clinicians And Patients

What are the takeaways for safe, effective use of repaglinide?

Repaglinide is a rapid‑acting meglitinide indicated for adults with type 2 diabetes who need targeted prandial control, especially when metformin is not suitable.

Start low and titrate weekly with SMBG support and periodic HbA1c checks.

Be vigilant for hypoglycaemia, avoid gemfibrozil and assess renal and hepatic function before and during therapy.

Check local formularies and the SPC for up‑to‑date prescribing details and regional availability.

If a patient or carer needs counselling on dosing timing or hypoglycaemia management, provide a simple dosing flowchart and a written action plan.